RIGL (Rigel Pharmaceuticals Inc. (New))
Insider Trading Activity
Every open-market purchase and sale reported by RIGL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | David A Santos | EVP, Chief Commercial Officer | F | — | — |
| 2026-09-03 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | F | — | — |
| 2026-09-03 | RAUL R RODRIGUEZ | CEO, President | F | — | — |
| 2026-09-03 | Dean L Schorno | EVP & Chief Financial Officer | MIXED | — | — |
| 2026-07-10 | ALISON L. HANNAH | EVP, Chief Medical Officer | A | — | — |
| 2026-06-24 | Kamil Ali-Jackson | Director | Sell | — | — |
| 2026-06-22 | David A Santos | EVP, Chief Commercial Officer | A | — | — |
| 2026-06-22 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | A | — | — |
| 2026-06-22 | RAUL R RODRIGUEZ | CEO, President | A | — | — |
| 2026-06-22 | Dean L Schorno | EVP & Chief Financial Officer | A | — | — |
| 2026-06-22 | Lisa Rojkjaer | EVP, Chief Medical Officer | A | — | — |
| 2026-06-03 | Dean L Schorno | EVP & Chief Financial Officer | MIXED | — | — |
| 2026-06-03 | David A Santos | EVP, Chief Commercial Officer | F | — | — |
| 2026-06-03 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | F | — | — |
| 2026-06-03 | RAUL R RODRIGUEZ | CEO, President | F | — | — |
| 2026-06-03 | Lisa Rojkjaer | EVP, Chief Medical Officer | F | — | — |
| 2026-05-28 | Kamil Ali-Jackson | Director | Sell | — | — |
| 2026-05-19 | Jane Wasman | Director | A | — | — |
| 2026-05-19 | Mark W Frohlich | Director | A | — | — |
| 2026-05-19 | ALISON L. HANNAH | Director | A | — | — |
| 2026-05-19 | ANTHONY GREGG LAPOINTE | Director | A | — | — |
| 2026-05-19 | WALTER H MOOS | Director | A | — | — |
| 2026-05-19 | MICHAEL PATRICK MILLER | Director | A | — | — |
| 2026-05-19 | Kamil Ali-Jackson | Director | A | — | — |
| 2026-02-24 | WALTER H MOOS | Director | MIXED | — | — |
| 2026-02-19 | Dean L Schorno | EVP & Chief Financial Officer | A | — | — |
| 2026-02-19 | RAUL R RODRIGUEZ | CEO, President | A | — | — |
| 2026-02-19 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | A | — | — |
| 2026-02-19 | Lisa Rojkjaer | EVP, Chief Medical Officer | A | — | — |
| 2026-02-19 | David A Santos | EVP, Chief Commercial Officer | A | — | — |
| 2026-02-12 | Dean L Schorno | EVP & Chief Financial Officer | F | — | — |
| 2026-02-12 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | F | — | — |
| 2026-02-12 | Lisa Rojkjaer | EVP, Chief Medical Officer | F | — | — |
| 2026-02-12 | RAUL R RODRIGUEZ | CEO, President | F | — | — |
| 2026-02-12 | David A Santos | EVP, Chief Commercial Officer | F | — | — |
| 2026-02-04 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | F | — | — |
| 2026-02-04 | Dean L Schorno | EVP & Chief Financial Officer | F | — | — |
| 2026-02-04 | David A Santos | EVP, Chief Commercial Officer | F | — | — |
| 2026-02-04 | RAUL R RODRIGUEZ | CEO, President | MIXED | — | — |
| 2026-02-03 | MICHAEL PATRICK MILLER | Director | A | — | — |
| 2025-12-29 | Dean L Schorno | EVP & Chief Financial Officer | M | — | — |
| 2025-09-17 | RAUL R RODRIGUEZ | CEO, President | A | — | — |
| 2025-09-17 | Dean L Schorno | EVP & Chief Financial Officer | A | — | — |
| 2025-09-17 | Lisa Rojkjaer | EVP, Chief Medical Officer | A | — | — |
| 2025-09-17 | David A Santos | EVP, Chief Commercial Officer | A | — | — |
| 2025-09-17 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | A | — | — |
| 2025-05-28 | Jane Wasman | Director | A | — | — |
| 2025-05-28 | Kamil Ali-Jackson | Director | A | — | — |
| 2025-05-28 | Mark W Frohlich | Director | A | — | — |
| 2025-05-28 | ALISON L. HANNAH | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 292,774 | — |
| — | CEO, President | 273,362 | — |
| — | — | 112,385 | — |
| — | 10%+ Owner | 79,962 | — |
| — | 10%+ Owner | 78,770 | — |
| — | EVP & Chief Financial Officer | 78,362 | — |
| — | EVP, Chief Commercial Officer | 61,622 | — |
| — | EVP, GC, CCO & Corp Sec | 50,559 | — |
| — | EVP, Chief Medical Officer | 35,025 | — |
| — | EVP, Chief Medical Officer | 34,003 | — |
| — | Director | 18,472 | — |
| — | Director | 18,250 | — |
| — | Director | 18,250 | — |
| — | CEO & Board Chairman | 18,068 | — |
| — | EVP & Chief Commercial Officer | 16,500 | — |
| — | EVP & Chief Medical Officer | 11,550 | — |
| — | EVP, Pres. Discovery&Research | 11,136 | — |
| — | Director | 10,125 | — |
| — | EVP & CFO | 10,000 | — |
| — | Director | 10,000 | — |
| — | Director | 7,500 | — |
| — | EVP & CMO | 7,246 | — |
| — | Director | 7,000 | — |
| — | EVP Corp. Affairs, G.C., Sect. | 6,026 | — |
| — | Director | 5,937 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RIGL quote page; the site-wide leaderboard is on the insider transactions hub.